CYRX - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by. This is the conference operator. Welcome to the Cryoport’s First Quarter 2021 Earnings Call.

As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. now Managing turn opening Partner would to conference remarks. I Fromer, Todd of Instructions] like the to over [Operator KCSA for Please go ahead.

Todd Fromer

operator. you, Thank

and everyone beliefs expect contains statements. team. are Before on this available operating statements are not performance, begin today, forward-looking developments would These and occurring our to we based to that in or we future I that address statements conference anticipate currently on forward-looking certain management remind call assumptions events statements. or management’s All forward-looking information like our that the

Our as management team believes that these forward-looking statements and are made. reasonable when

However, publicly speak on events, any only update required forward-looking statements, or you undertake a made. such statements the undue as by of law. not such when revise of future date any because should or not as new information, as We or whether place to forward-looking result except obligation reliance otherwise, do statements any

pleasure floor the Jerrell the and Cryoport. Jerry, those and time with is and which Officer Shelton, of are is Exchange on cause to risks in experience to, Form Factors, XX-K and present in statements Commission. include, filed yours. our described risks historical or subject Chief with turn and from Securities certain my described events forward-looking not are elsewhere but over Risk reports, now file differ Securities to call uncertainties we time from Exchange Item those to our These projections. results, the to and addition, annual developments Commission expectations report Executive in other It actual XA, In materially to could and our that the the limited uncertainties and Mr.

Jerrell Shelton

Officer, today. ladies Development Vice appreciate Sawicki; Stefanovich; Heinzen. of Good our Relations, Robert and Mark and Investor our Todd. Financial our our With Chief you, you joining and earnings Scientific We Dr. Chief afternoon Thomas this is Officer, me call afternoon, President Thank gentlemen. Corporate

in quarter first and This to provides and have can general Presentations performance, uploaded outlook. under website. reminder, It found a XXXX Events financial our be a our our section document section. and As recent operational we the Relations and review of Investor review business document the

would go to the If you read website I and not to a you to had download chance it, encourage it. have

Now a update questions brief regarding first your general results. our for by followed quarter

accomplishments position Following supply markets. with leadership we chain Animal our with for Biopharma/Pharma, unrivalled major our in XXXX market-leading an temperature-controlled XXXX, and solutions Health entered Reproductive

that now platform a a locations, consists of companies and mutually products. global family Our of and provide solutions, services XX reinforcing

a our revenue the platform first performance anticipated, with delivered for growing new million. As quarter, outstanding to record $XX.X

recent strategic XXXX we acquisitions acquisitions, Since closing, ongoing fuel performance each we gene on sharpened significantly Our positioning as and in and excellent their the this therapy growth Solutions navigated Solutions of and made us Biological investments these for two to excellent to of focus have market the contributed Biological beyond. team’s integration cell CRYOPDP teams. CRYOPDP and MVE MVE growth, and

neither As were the growth markets. MVE high medicine Solutions part large on focused very regenerative companies, of a CRYOPDP, Biological

leverage which the global can strategic Asia defining pipelines strides resources growth capture. accelerate the in and aligning Osaka, innovation expertise Cryoport since of market we respective the joint and Japan, these the Systems stoking and in example short identifying region. will launch logistics of recent focus, our support to product Now, center further of synergies, businesses. resources, In significant new One each in as is acquisitions, Pac deep these CRYOPDP’s Cryoport, a growth made have closing and and we time accelerate

the the basis, from industry a we as XXXX. and And of revenue focus the business record generated represented total strategic over year-over-year Cryoport record invigorated anticipate of than of We XXXX. quarter As for growth very revenue approximately Biological XXXX. monthly, time Commercial as regenerative At quarters our XX% our five-year units. have as growth we are of Biological by of was both,, MVE sequential global XX% our Through primary scaling their that an potential compared facilities Biopharma/Pharma and rate historical Cryoport’s over a throughout records both, teams, was and broad running to between Solutions customers with from and introduction part continue strengthening two full our MVE growth well dedicated Cryoport for quarter early our at are pro were rates. And continued Novartis’ we higher of I agreements, trials, million and fourth of previously a growth continued Solutions, both the capacity, XXX CRYOPDP XXX total newly to market revenue we benefits also and Cryoport, of and expressed, quarter supported our The overall significantly Revenue the CRYOPDP breaking believe Gilead’s with the reach revenue direction. out these on driver the and primarily KYMRIAH growth potential expanded first -- dedicated increased for end production trials record first CRYOPDP of revenue of the underway. continuously the our footprint, is purpose. from these to market organic I’d anticipate over emphasize reaching of indicator XXXX. like units reported investments build growth commercial these by $XXX and now YESCARTA. a as with are two number year-over-year. supporting of MVE clinical within medicine it operating and our synergies forma first Systems, achieving ongoing a pipeline our at well period business cost that

Cryoport’s supporting cell commercial mark sixth received cell therapies bio FDA treatment CAR of long-term global and addition, myeloma. the In has a Bristol-Myers gene received therapy approval Abecma, seventh have launch bluebird a therapy. and CAR and first-of-its-kind agreements T-cell for for therapy its multiple Squibb FDA and BMS approval their therapy, T-cell of for These BREYANZI, the

agreements the filed growth quarter of Regenerative MAAs MAA information revenue throughout year, Alliance the of We based And the expect total forecast XXXX BLA contribute submissions looking were our A in additional commercial to forward, these Cryoport or Medicine. our XX of and products internal from three first supported BLAs begin the anticipate or to the in of to in and Cryoport driving quarter remainder revenue XXXX, supported for on to second XXXX. we for ramp in during XXXX. up

market we premium services, healthcare our biopharma/pharma up Australia, solutions increasing the specializing for time demand and and our focused logistics Osaka to for APAC sensitive in Australia. In growth regarding leader back in addition on to medical industries management in the organic Transport Solutions region, a supplemented opening due and support critical Critical

strategy, in chain clients the step the throughout CRYOPDP we of more CTSA, an to our supply business our number APAC the important initiatives, of as providing in also international need trials clinical unit, the CTSA able well CTSA CTSA The part temperature for the serve a acquisition Cryoport have in support will Australia. will with continues addition Systems is expected support control region. domestic increase. APAC As robust as solutions to be as the market Cryoport’s, effectively, who of as on region impact strategic is to of APAC Australian

Now, questions. for like open request I’d to lines that operator the the

Operator

The Couillard with Brandon first Jefferies. comes question Instructions] [Operator from

Matt Andrews

Brandon. Thanks for on for taking Matt questions. is my This guys. Hey,

for First, Jerry. to start, maybe

the plus five any to about on offer synergies as key again areas going identify through additional and over on You synergies just million continue the excited talked them you color look few you most today, execute XXX then here? over you’re what to mentioned remain of next the you’re Can portfolio process of across years, the and on years and those work maybe at them focus schedule. about

Jerrell Shelton

opened give can as a between lot you also freight well. of CRYOPDP. Cryoport of I and is third up process mentioned commentary, joint point can that the Matt, of you my have operations much tell can’t where I coming that then, a you in a Well, center think joint Systems. I we in specifics. to CRYOPDP way the joint I know was to our operation And we parties through in Singapore that going of we

of or anything add to But, to can of number those me time. a I initiatives things are to that for on. them one hard are are go that, at that them you all It’s want there tell through categorize to you So, well Mark? going Do underway.

Dr. Mark Sawicki

Yes.

through third and others. better partners, more think, freight Jerry cost power between side, for on systems management discounting parties, on ability lot and cost the product relates spend that and was we PDP platform The operational I pricing side, the transportation leverage example. to provides and consolidated airlines with like structures scheduling mentioning on or to But more so a side have also, speak. the the to

that’s on spend So, just example for another side the you.

Matt Andrews

are also you strategic the Health with to most service added a engaging in noticed I really XX-K in your contract Syneos your guess, it clients shouldn’t it looks platforms service in you we then, partnership exclusively But with be And given and language mutual added in order Lonza. their across base? CROs some services surprise, CDMOs both client your that So, here XQ. conjunction recent

forward, for expanded and expectations expand have upon you this portfolio going you accelerate to services? include of to these kind So, of of about Cryoport’s relationships the talk can them ability, type the and guys

Jerrell Shelton

relates platform. comprehensive to into ties a as This Sure. chain strategy it an overarching putting supply together

through into in acquisition services is doing overall a the obviously, we this products. organic-related we’re very through don’t have a an interest So, in very, But chain of And and partnerships. workflow but a to types manufacturing manufacturing of and side. Obviously, is for build the other different key element managing competencies, of supply ways. these the this component of side of moving out couple

don’t want particular Lonza build example, an asset this and need, themselves. So, out recognizes this they to

mutual engage advantageous view to provide that relationships and well it clients, as parties. respective together our unified as platform for our mutual establish a their they ties for base client as who themselves strategic So, business

some a different it Lonza, And integrate happens so also We format. business example, for of product systems CDMOs. offer It that business it in so, into does offerings of of our thing Lonza contracting some ways. our example is our this integration profiles, And process. a directly of through activities or and their is can with part number our on second happens other in for the of obviously

a is add that, it and base, risk So, how that’s as as client just examples a or them. the of well for for reduction value element occurs. this maybe a couple

Operator

B. Please go The D’Silva comes ahead. next Andrew question Riley. from with

Andrew D’Silva

selling might a the molecules biopharma, more be of biologics therapy start, relevant us recent small So or or just other sense to tied just can what percent regenerative medicine to space of acquisitions? gene of of that kinds some maybe the give are you versus within with specifically sales

Jerrell Shelton

for That’s Mark, a question Andrew.

Dr. Mark Sawicki

the of or medicine Yes. you look of focused. business if the the complex. It’s is within has pharma traditionally whereas Primarily, organization a majority regenerative historical little business bit biopharma plurality more been it business, the the vast systems bit focused PDP at is the a focus,

time. And obviously I so, give will this numbers over that at But, you shift point. can’t exact

Andrew D’Silva

I not contract terms? XXX% Okay. it’s you, And about it Fair this. for I sure, even was relationship to as a been I’m thus enough. that’s or Novartis’ renewed couple with believe but far just relates get original renewed, Gilead questions it their

Jerrell Shelton

were last contracts No renewed year.

Andrew D’Silva

was And approaching you some majority are doing While sign your correct the it’s fair all customers customers. to I it Is might statement? of a your I instances. digging many your there to platform? be overwhelming treatments utilizing a contract, with in typically when And committing some that XXX%, of XXX% not logistics Okay. effectively, say, am

Jerrell Shelton

Yes.

Andrew D’Silva

And BMS’s approved legacy to quarter? recently still material it during And CAR-T, Cryoport you relates contributors were they the perfect. be then, to contributors them sales? expect Okay, to Systems as do

Jerrell Shelton

QX to They series contribution significant a be perspective. revenue. contributor quarters a not were next of in will our the They from

Andrew D’Silva

me And gross could significant reason MVE rather quarter-over-quarter the know, us was improvement what just you for in the let margins?

Jerrell Shelton

tell we that. you Yes. can Certainly,

Robert Stefanovich

Yes.

and about on with to and the sciences to the of we If at you’re therapy revenue CRYOPDP improved those moved most to have had side elasticity to a see was and that margin with results as quarter, really the the that and life in -- the time, cell overall they But improvement you profiles. quarter revenue of their for expect units, the for obviously their We’ve absorption actually gene revenue With look within continue. the compared well. including absolutely you’ll talked that the as With all QX to margins rates business growth record segment we that past industry, MVE compared part in margins. and contributed there that’s respect higher right, towards sequential it that, to historic related increase seems growth. obviously this, the mostly growth improvement overall and over

Andrew D’Silva

me the partner just be in couple maybe question likely? health. it context. Zoetis quarters quarter-over-quarter, part mentioned for Is site or animal even of health useful A to you substantial is just tied Last that ago, of increase the on really recent Okay, all for would reason M&A? animal

Robert Stefanovich

historic animal animal on related level that business MVE Systems opportunities to brought not the for on highlighted. an There’s health, increase just health. the This been is to that but the you in that well the really table as terms to side of Cryoport

Jerrell Shelton

those because travel, to support given as opportunities of to are and that still it pushed work. in But, validating They’ve degree been relates COVID-related on place. facilities restrictions qualifying a to

Andrew D’Silva

Okay.

of me. for of Best hop color new forward Okay, going partners Well, those they are in and that’s good back great. on. who you queue. luck see it some when come forward. look I’ll That’s to

Jerrell Shelton

you. Thank

Operator

Paul Knight ahead. KeyBanc. Please comes go The next with question from

Paul Knight

very Jerry, then that? revenue therapy add you says down above approved and the trial my clinical revenue growth year-over-year. XX%; color strong, was math Could was around

Jerrell Shelton

can. we that defer certainly I’m going Yes, question And Mark. to to

Dr. Mark Sawicki

Yes.

And others As of talking this, Japan, about Kite, you expansion, guys This is portion from in shift we’ve overall to small and shipments know, seen in last was global those opened you’ve lockstep manufacturing Novartis Singapore what with moving expected. facilities the over international new we’ve strategies. XX global which And months. in domestic. their multiple been seen a tight our

facilities We manufacturing we’ll expansion and effectively volumes And XXXX. are increase. capacity their we guys’ seeing that triples through this are long-term. recent trend commercial continue confident of These see accelerate shipping

standpoint for quarters. the the of from coming So just we’re over shipments with months, are it the Novartis of clear, the opportunity very Gilead, Abecma still very, and to last the supporting the make both revenue BREYANZI and therapies, commercial we ramp and couple bullish TECARTUS a all new launching on over and

Paul Knight

Phase is trial was Okay. Phase rate you then And talk on online, Could XX%. two growth up was growth, X XX%, back overall items? and XX%, are the coming the or trial X academics those to growth

Dr. Mark Sawicki

determination on to Yes. It’s we at is to reinitiate. a these all more clinical opportunistic, when as the it back make all pre-COVID pipeline, have, relates that patient to centers these levels. companies the enrollment data Based

So, we don’t think that whatsoever. that’s a factor

related more clinical now their strategies. it’s So, to

Paul Knight

Okay. or from you is it But, us? And CRYOPDP can’t guess, COVID the can’t really MVE help are quantify it. I theory, you getting if much any to could you how and I -- that? performance helping, is COVID talk know --qualitatively

Jerrell Shelton

COVID Paul. not a help, No, is significant

that come We’re cures, trials. where or however replenishment some that supply a focused selling gene in area. number of vaccines. we the into for not on And dry to the therapies have is therapy. We But, world some it do And trials supporting in do, play of -- do we’re support in cell and significant parts ice we us. of of we gene therapy significant terms

We are therapy. selling focused on gene

Paul Knight

strong guess, I CRYOPDP seems cetera. attribute, like Yes. too? you performance labs et would MVE, really reopening what this and mean, I And with helps,

Jerrell Shelton

a The companies that’s strategies is and just cell therapy, and process strong gene the performance beginning, beginning. in on has both a focus that’s to and sharpening just do just with

Paul Knight

that landed guess, I the I the not then, would be guess, quarter last question And I year? they regarding [teams] my ramp, Abecma weren't guess significant they the would BREYANZI. you were rest in and in quarter at then and assume, I of those, the

Jerrell Shelton

correct. That's

Operator

Needham. from next David comes with Saxon The question

Unidentified Analyst

for David. on Joseph is This

beyond? say, in and Just with to you side the fairly you're side your reproductive that you maybe the the demand on some wanted to or business? XXXX business, medicine increased Can you seeing grew Concerning maybe this maybe in suspect backlog, touch your discuss strong partners remain quarter. of on that the the nicely throughout do let's of pretty

Jerry Shelton

we're remember, well. reach our as expanding Well,

increased So demand. we have

evolving We our reach. Mark, we're strategies much other expanding have and are improving we'll comments some sure consistently have our effectiveness that that. And I'm on

to him. turn I'll So

Dr. Mark Sawicki

key Yes, now in is international mentioned, Jerry built reproductive this a outreach there's standpoint put medicine from two factors. is team had we key really the into of of strategy those, with And are large we networks phenomenal sustainable. markets. forward the in the for We’ll reiteration absolutely significant space. relationships an really as we to that's together a XX medicine partnerships One, source the ago global those profile a increase that global that And believe, with clinic support support and on a pushing months folks. full establish [refractory] of team And basis establish space. second a moving both the

Unidentified Analyst

in whether the maybe Can clients choose maybe terms gene of the cell some and one be then And clients. between it’d I of therapy guess, shippers, high or bit Cryosphere or shippers, more the on level, advanced potentially is high volume little when us give just your you these different little information a how shipper, your launched?

Dr. Mark Sawicki

and on product, quality their packaging need. what dependent really It's configurations to they their organizations as

flexibility they And that is have so a good of lot thing the of choice.

to it is have in best us relates class. on As we and that everything the market

so the mandates And whatever determination. organization is dependence how they typically that on make quality

Jerry Shelton

to agile tools Remember, needs. a fulfill solutions the company. Joseph, and we have in We're clients’ which we're

we in those And so vary needs. they vary do we way and fulfill the

Unidentified Analyst

And I preclinical guess little is more use bit academic volume high commercial shipper, research, have the that specifically. clients a more you? towards Do what maybe or

Dr. Mark Sawicki

an a typically format. blood needs on from used neck smaller therapy. high packaged smaller for our format unit, because whether they're straightforward they're pretty Allogeneic an a It's the in It's much opening volume cassettes autologous vial blood it’s that of opening use allogeneic based which traditionally heavily draws. perspective. therapies a has using -- that typically that that autologous [neck] being wider an therapy, If are for the dependent or it's

Operator

comes The Sourbeer with question from John next UBS.

John Sourbeer

strong for about to continuing you And of you pent see you coming with around were like digit seeing there XX% calculations, demand talk it year of this business the growth MVE up trends you're are accelerate my for terms do throughout revenues out year, and COVID? any double comfortable sequentially. MVE? biopharma in From looked Can the

Jerrell Shelton

distributor network mean, I give And animal storage Well, I and has therapy. health, a we're you'll of been gene guidance in has support And exceed up of gene it's for that it the will will and some it’s sense. about that through it’s as There's demand growth cell we about focus of strong it what will course, all in MVE vaccines in company refocusing a pent growth And towards well. But historically. in per the our no on focused number said, COVID work the in as to therapy. markets MVE. and growth stronger numbers. we area. to we it’s it that supply strong don't systems the in are certainly the in Cryoport see and sharpening strong strategy and trials -- se And continue continue strong say is we served to get our hasn't service it's doing biologics, it it And been already continued and cell there and but safe just traditionally.

John Sourbeer

And about Australia. China? talk in know then in deal the as Can including and outlook, expanding you CTSA quarter future announced expanding into deal the area I such you the and M&A any

Jerrell Shelton

we Well, and in strategy. developing definitely that China we're be will

and under for we there. Now, it's be some been consideration will time absolutely

in going I to now. Asia-Pac is but there of we have out are we will We grow. have a there, and because today presence bigger mean China shipments

we're filling out strategy. strategy Asia-Pac We Asia-Pac have and that an

does the you will of And especially in a continue It in be in things a on there packaging we certainly buyer we'll growth about It'll in have area. lot technology. area, do the that We're organic have with supplement we information courier terms in talked It a take past. logistics eye and of robust be But that pipeline. a at things in are certainly our of the to our the a with and and acquisitions, things. looking rate seller. be lot In I've categories of acquisitions. it'll traditional

on along. primarily. come they the growth, acquisitions will our acquisitions, is organic focus is however, on supplementary will focus, Primarily, be Our not and

John Sourbeer

on quarter, And early think strong by I And ,or is around I see comfortable any doesn't for guidance, the Looks the in like consensus Are in number the year. lastly, consensus you growth guess revenues. provide street do million was company year. I you it’s current XXX I know organic with upside? know the XX% around that but

Jerrell Shelton

And right with comfortable feel very that And we consensus good we're about and Well, track think on we did beat number. we a happy now. that. we're

Dr. Mark Sawicki

for remind we're just focused accelerated obviously, cell that and primarily again, is And market, to on, market therapy poised you, gene the the growth. really

launches. we're see now that commercial seven already You supporting

So there's to where we right certainly [Indiscernible] upside now. potential

Operator

The with next question comes SVB Souda Leerink. Puneet from

Unidentified Analyst

This Puneet. Scott for on the is

ahead would you're the on side, a of the PDP. identified want talk to you nice provide of just that our of the pandemic? recent of -- a So kind you there, just in and I Cryoport more congrats MVE strength, through be was the on synergies revenue that If both any little to legacy the kind into and little estimates you bit Could of if get the a what on MVE and quarter could little PDP then of kind of come acquisitions. more kind bit early great. color strength out on recovery seeing

Jerrell Shelton

Cryoport five on is of years. a in the a that about the biggest next between the that. So And to we've comments CRYOPDP is and make terms the of Mark over few good $XXX million synergy systems promise in thing synergies position talked

Dr. Mark Sawicki

focus confident target line obviously that's towards from that So over some perspective. that firm that. we $XXX are four we there's see the million of a to in And and of starting clear that a ours and years next contribution been feel sight

to have in I through which this but are mentioned processes, at are approval know from the very to some takes the had vendor situation. equality a you go of Q&A situation PDP time, potential we and pipeline moving Obviously, time. Jerry active actively earlier the think point third party the that in those you

Jerrell Shelton

of the subtle primarily different -- your market, the more they're the market views terms MVE, comes about And are it different from In there synergies definitely those of there. supplementary. view and question two and a are

subtle. so they're more And

Unidentified Analyst

the from on is of they’re I partnerships out companies, Ultracold, competitive pending landscape, a a just kind Stirling and as building this, been to from a also seeing of change a to such anything few cryogenic provide capabilities. Could environment, which side, BioLife, in more be there, new competitive we've by touch kind cryogenic just is a in CMOs? on speak [attitudes] CMO just bit Just the any employing you Catalent this of kind little great. color there want where acquisition their the guys is you that'd

Jerrell Shelton

in No, the environment. competitive there's no change

fact, Cryoport what And and a their In build and see that's partner therapy they but is have and in they're is e-products. have for systems, manufacturing Catalent doing. customer and we out use to normal use gene storage they of course the cell they company,

is very So we that all see positive.

Unidentified Analyst

those for estimates. funding one in gene of new Has new new for that of therapy that levels you of funding of year kind Last for clinical an and we are it incredible XXXX you last importantly, kind almost slowed was last yet? with And down funnel guys of seeing any year? all XXXX, the kind year seeing cell customer, trial Are our customers by more doubling that, me. new to expand formation saw

Dr. Mark Sawicki

XX quarters, think months. So coming in new also commercial from companies startups cropped cycle activity number funded. substantial that there well will of the the of extremely a clinical about in been activity a the up and augment is are period continue last have that over the to time existing but have for two year obviously, last And if you it that perspectives,

additional most pharmaceutical quarter in in well, and very for space of listed the startups and in is recent quarters very, a this general. our active have a couple bullish be the because very coming as industry we We to those review anticipate

Operator

from Baldry comes Partners. with Capital The next question ROTH Richard

Richard Baldry

of up And two MVE you’re sort about expensive of its of is then does think growth and as we that levels, of at tick of rates it maybe sustainable in maybe the or argue these with increase how them rate concepts. capacity? closer It’s full revenue One, time of level of into focused more sort that the you area be on. sort incrementally capacity, to the cost terms of kind higher should out build When biologic at capacity running out. you're growth seeing

Jerrell Shelton

-- in it mind, with so of in Rich, growing we plans. bought in us, our all is new this the it's to none

this I stage, matter better we team. mean, a couldn't asked so optimization. have it's a fantastic MVP. a team that I And And for at have an of we have

we have Prague, a and plants, three plane Chengdu, Ground, in and Georgia. China New Minnesota Ball in have We

be and we promise we now optimizing new some and for lead But a up plant at we'll while. demand. And there's and have location optimizing plenty additions will that wouldn't those So I time at that's are point. of that'll keep plants the this certainly with a a maybe time continue have right but you certainly possibility. to

Richard Baldry

sort build of Which any forward? line QX, And baseline numbers look more to to of off into below seems going the this of QX XX. then if side a acquisition we that Does QX? like is there Were QX comparing sustainable we sort look of to numbers with one the fell SG&A went forward? time those good XX feel as from

Jerrell Shelton

it's I baseline. a good think

make. can I some building at end QX related year have even we related you exclude see they acquisition the you there the just but to is, typically that’s and some the in though resources, plus increase if look we that end were it, some at there you remainder I year all additional costs, out increase it of -- year of typically, think think those

good is QX starting point. So

gradual Now resources. just additional on can some assume you building out increase

Richard Baldry

quickly? system, six million-ish fully to operationalized the moderately we've building it from R&D, this basically over like doubled from months on to question four. forward similar or maybe X from gone a up Does feel point a this first quarter And last quarter start numbers

Jerrell Shelton

that's too it’s Rich, early number. stabilized tell to that a you

sort our couple staffs, in the of next a tremendous open small -- for that first We And that that very in and the be probably -- Fusion of will and in cryogenic our Fusion There's and our last segment Cryosphere will will plans and that's development last last don't that a a research of have temperatures have are first of pipeline. sourcing. things things. facilities this we be our market of thing on do innovation And product we XXX part half know the that you especially other other part that introduced a smaller or and several of in in of have the the areas surfaced up and year year number this year, things have some very keen big innovation us, to robust and pipeline. plumbing there a engineering the are cryogenic

move tell -- So something as now. that we'll slightly -- along. totally be and tell today you could It go keep could it just that wouldn't you but I But right posted I that can't is that up on will it you in we that neighborhood, that's stable. number

Richard Baldry

you drive savings, with shouldn't coming would X And general around of revenue sort guidance, or quarter You about revenue that your factors that through EBITDA side the concept time or give generating very products higher. stepping just there's the any with thoughts adjusted up consider new we arguably consistent that the online one talk thought there approval million. QX to service of in don't the since commercial a cost Are any rest year?

own? sort adjusted new of our in when that we there to we if sustainable mind seasonal need are EBITDA or on any keep curious things reforecast high So and

Jerrell Shelton

Yes, just adjusted wouldn't seasonal eliminated to we've already lot a maybe onetime particular, address in say EBITDA. I of that anything that. elements, there's the

pretty a that's clean So number.

the us see dynamic includes in again, our that you move Jersey chain as Houston, will going forward, vendors New online you with Now bioservices. supply in this market, in

I adjusted [EBITDA] start forward all then of project to the the come and those will mind weigh But seeing the a the just building you'll things it's good organization. bottom volume out So in through top, as use on have into to line temporarily it’s full think they layer business the number through. the

Richard Baldry

Last question, level, again, guess. very I high

Your adjusted the total is quarter EBITDA than now your higher 'XX revenue that long of ago. not in first

think that in business? on balance more stay the be basis scale put position in have more you to terms important sort to forward maybe disciplined does top a go to you and So Or bottom and acquisitions of line? up of it's a aggressive, do

Jerrell Shelton

investment and we take use Cryoport. disciplined fantastic don't spending, shareholder in But than around very the the us Well, think we funds. are word seriously Rich, word use position. term any We puts I other even more it we use a we

grow this we reach, solutions market industry we and to continue So develop to to But This rapidly. and that are and we our be grasp and grow we also to And leader that's as that meet to grow. growing continue aggressive and disciplined. our compelling be to and too supply market so will comprehensive rapidly. more is the growing chain very intend will be evolving

Operator

comes Stephens Johnson question next The from with Jacob Inc.

Unidentified Analyst

right one quick just to a interests you on Should side? for Nathan high focused and that some me, from Jacob. product the is a one the light bit on Is on or area expand level. either It's on? think just there services can you M&A now side little from if more Maybe this within we any shed

Jerrell Shelton

and What accretive the be an But being sector, The that our met with can't information a side on services endeavor a place. we sense, interests have is execute in found company, me if strategy. synergistic I very to company well we preference criteria product we'd being preference and the a that much being we or our made say on to for either run have acquisition our of continuing talking to the them.

Operator

back for session. any the like to concludes remarks. This question-and-answer closing I to would Jerrell the turn conference over Shelton

Jerrell Shelton

the starting growth and the That In and outsize number MVE you, and questions. we offering and Biological all from follow in the and dialog your a strong growth Solutions $XXX terrific on was January, Cryogene, had, with thank of significant trials support very for the first you, supporting, clinical growing Cryoport million we public XXXX. our appreciate continued quarter quarter to in performance in closing outstanding successful the position growth. year, of of just our achieved strengthen and following was CRYOPDP systems first a that questions. closing, quarter fourth Thank future We operator financial further

life very the that And a to global regenerative unique and us of development support to and our clinical today positioned joining especially to our as develop. call. our continues Our biology industry competitive we and solutions you medicine extend you our next for call highly We differentiated want world. thank sciences until drive of the acceleration platform the We and capability field widened around good and bid anticipate continued mote therapies earnings of operating to will growth evening. stage our commercial continue our

Operator

today's concludes This conference call.

you disconnect Thank pleasant day. a for lines. your may have and You participating,

Cryoport (CYRX) 5 May 212021 Q1 Earnings call transcript